Phase lb combination trial of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with locally advanced or metastatic solid tumors

被引：0
|
作者：
Infante, Jeffrey R.
Gandhi, Leena
Shapiro, Geoffrey
Burris, Howard A.
Bendell, Johanna C.
Baselga, Jose
Hsu, Karl
Faivre, Thea
Asatiani, Ekatherine
Heist, Rebecca Suk
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Sanofi, Cambridge, MA USA
[5] Merck Serono SA, Geneva, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3118
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors
    Jean-Pierre Delord
    Antoine Italiano
    Ahmad Awada
    Philippe Aftimos
    Nadine Houédé
    Céleste Lebbé
    Celine Pages
    Thierry Lesimple
    Monica Dinulescu
    Jan H. M. Schellens
    Suzanne Leijen
    Sylvie Rottey
    Vibeke Kruse
    Richard Kefford
    Sandrine Faivre
    Carlos Gomez-Roca
    Armin Scheuler
    Giorgio Massimini
    Eric Raymond
    Targeted Oncology, 2021, 16 : 37 - 46
  • [32] Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial
    Awada, A.
    Delord, J. P.
    Houede, N.
    Lebbe, C.
    Lesimple, T.
    Schellens, J. H. M.
    Rottey, S.
    Kefford, R.
    Rejeb, N.
    Raymond, E.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 185 - 186
  • [33] Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models
    Gravina, Giovanni Luca
    Mancini, Andrea
    Scarsella, Luca
    Colapietro, Alessandro
    Jitariuc, Ana
    Vitale, Flora
    Marampon, Francesco
    Ricevuto, Enrico
    Festuccia, Claudio
    TUMOR BIOLOGY, 2016, 37 (01) : 341 - 351
  • [34] Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
    Ramesh K. Ramanathan
    Daniel D. Von Hoff
    Ferry Eskens
    George Blumenschein
    Donald Richards
    Isabelle Genvresse
    Susanne Reschke
    Camille Granvil
    Adam Skubala
    Carol Peña
    Klaus Mross
    Targeted Oncology, 2020, 15 : 803 - 803
  • [35] Phase Ib study of the oral PI3Kδ inhibitor linperlisib in patients with advanced solid tumors
    Li, Jin
    Xue, Junli
    Liu, Tianshu
    Feng, Yi
    Xu, Nong
    Huang, Jianjin
    Yin, Yongmei
    Zhang, Jun
    Mou, Haibo
    Shentu, Jiangzhong
    Bao, Hanying
    Xu, Zusheng
    Xu, Zuhong
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, 30 (02) : 241 - 251
  • [36] A phase Ib study of the PI3Kδ inhibitor linperlisib in patients with advanced solid tumors.
    Li, Jin
    Xu, Nong
    Liu, Tianshu
    Huang, Jianjin
    Yin, Yongmei
    Mou, Haibo
    Zhang, Jun
    Wu, Lihua
    Liu, Zong Liang
    Bao, Hanying
    Xu, Zusheng
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study in patients with advanced solid tumors
    Bendell, Johanna
    LoRusso, Patricia
    Kwak, Eunice
    Pandya, Susan
    Musib, Luna
    Jones, Cheryl
    De Crespigny, Alex
    Belvin, Marcia
    McKenzie, Meghan
    Gates, Mary R.
    Chan, Iris
    Shapiro, Geoffrey
    CANCER RESEARCH, 2011, 71
  • [38] A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumors
    De Weger, V.
    Varga, A.
    De Jonge, M.
    Langenberg, M.
    Mergui-Roelvink, M.
    Massard, C.
    Van der Vlist, A.
    Devriese, L.
    Goodstal, S.
    Zheng, W.
    Tuffal, G.
    Semiond, D.
    Mace, S.
    Watters, J.
    Demers, B.
    Schellens, J.
    Deutsch, E.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S55 - S55
  • [39] Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma
    Wen, Patrick Y.
    Omuro, Antonio
    Ahluwalia, Manmeet S.
    Fathallah-Shaykh, Hassan M.
    Mohile, Nimish
    Lager, Joanne J.
    Laird, A. Douglas
    Tang, Jiali
    Jiang, Jason
    Egile, Coumaran
    Cloughesy, Timothy F.
    NEURO-ONCOLOGY, 2015, 17 (09) : 1275 - 1283
  • [40] A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid fumors.
    Cohen, R. B.
    Janne, P. A.
    Engelman, J. A.
    Martinez, P.
    Nishida, Y.
    Gendreau, S.
    Wu, B.
    Felip, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345